Bactiguard (BACTI) DNB Carnegie Småbolagsdag summary

Strategic transformation and business model

• Shifted to a license partnership model, focusing on infection prevention for medical devices across five therapeutic areas, leveraging a scalable platform and validated technology.

• Achieved EBITDA profitability after a strategic change, with multiple consecutive quarters of positive results and a plan for continued double-digit growth.

• Set targets for 2030: over SEK 600 million in revenue and SEK 200 million in EBITDA, with more than 10 application areas in exclusive or licensed partnerships.

• Two-thirds of future revenue expected from existing partnerships (BD, Zimmer Biomet, wound management), with one-third from new deals.

Technology and product portfolio

• Proprietary noble metal coating prevents infections without promoting resistance, validated in over 250 million devices and 100,000+ patients, showing 70% infection reduction and zero adverse events.

• Major partners include Becton Dickinson (urinary catheters) and Zimmer Biomet (orthopedic trauma implants), with products on the market and global reach.

• Wound management portfolio, led by Hydrocyn aqua, targets chronic wounds and surgical lavage, showing strong safety and efficacy, with growth potential in Asia and new regions.

Market opportunities and growth drivers

• Addressable market exceeds $80 billion across targeted therapeutic areas, with high unmet needs in infection prevention.

• Expansion into new geographies and applications, including recent progress in cardiology through early-stage partnerships.

• Wound management business is headquartered in Malaysia, with distribution through both partners and a focused sales force, targeting high-need regions like India.